TheraRadar
Clinical-Stage Companies / Evopoint

Evopoint

Pre-Approval PRO BETA
19
Total Trials
2
Phase 3
10
Phase 2
6
Recruiting
172
Score

Pipeline by Phase

Phase 3
2
Phase 2
10
Phase 1
14

Therapeutic Focus

Bacterial Infections Advanced Solid Tumors Relapsed/Refractory Peripheral T Cell Lymphoma Follicular Lymphoma, Grade 1 Follicular Lymphoma, Grade 2

Clinical Trials (19)

NCT06776952 Phase 3 RECRUITING

A Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma

Started: 4/10/2025

NCT05204563 Phase 3 COMPLETED

Imipenem/Cilastatin-XNW4107 Versus Imipenem/Cilastatin/Relebactam for Treatment of Participants With Bacterial Pneumonia (XNW4107-302, REITAB-2)

Started: 7/31/2022

NCT07545603 Phase 2 RECRUITING

Clinical Study of XNW5004 Tablets in the Treatment of Relapsed and Refractory Follicular Lymphoma

Started: 2/14/2026

NCT06702605 Phase 2 NOT YET RECRUITING

To Evaluate XNW5004 Tablets in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma

Started: 11/1/2024

NCT07730580 Phase 2 NOT YET RECRUITING

Study of XNW5004 Tablets in Advanced Prostate Cancer

Started: 7/13/2026

NCT06799637 Phase 1 RECRUITING

Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments

Started: 12/1/2023

NCT06987500 Phase 1 RECRUITING

A Study of PARG Inhibitor XNW29016 in Patients With Advanced Solid Tumors Who Failed Standard Treatment

Started: 4/11/2025

NCT06702995 Phase 1 RECRUITING

Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer

Started: 4/19/2023

NCT07730515 Phase 1 RECRUITING

Clinical Study of XNW5004 Combined With CHOP/CHOEP in the Treatment of Untreated Peripheral T-Cell Lymphoma

Started: 8/15/2025

NCT06558513 Phase 1 COMPLETED

To Evaluate a Phase I/II Clinical Study of XNW5004 Tablets in Patients With Relapsed/Refractory Advanced Tumors

Started: 8/3/2021

NCT07327294 Phase 1 NOT YET RECRUITING

A Phase I/II Study to Evaluate XNW34017 in Patients With Advanced or Metastatic Solid Tumor

Started: 1/31/2026

NCT06022757 Phase 1 TERMINATED

Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19)

Started: 9/20/2023

NCT04802863 Phase 1 COMPLETED

Intrapulmonary Pharmacokinetics of XNW4107, Imipenem and Cilastatin in Healthy Subjects

Started: 3/25/2021

NCT04801043 Phase 1 COMPLETED

To Evaluate the Pharmacokinetics of XNW4107 in Healthy Adult Young Females and in Healthy Adult Elderly Males and Females.

Started: 3/2/2021

NCT04482569 Phase 1 COMPLETED

Study to Evaluate Safety, Tolerability, and Pharmacokinetics of XNW4107 Alone or in Combination With Imipenem/Cilastatin

Started: 7/10/2020

NCT04040907 Phase 1 COMPLETED

The the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of XNW3009 in Health Subject

Started: 11/13/2019

NCT04787562 Phase 1 COMPLETED

Pharmacokinetics of XNW4107 in Subjects With Various Degrees of Renal Function

Started: 2/25/2021

NCT03901950 Phase 1 COMPLETED

Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of XNW7201 in Subjects With Advanced Solid Tumors

Started: 7/1/2019

NCT07707674 Phase 1 NOT YET RECRUITING

Phase I Open-Label Randomized Multicenter Study of XNW28012 Monotherapy in Metastatic Pancreatic Cancer

Started: 7/30/2026

Drug Candidates

XNW5004 tablets XNW28012 XNW5004 ; Chidamide placebo XNW34017 Combination of Imipenem/Cilastatin and XNW4107 Imipenem/Cilastatin/Relebactam XNW29016 XNW5004 XNW4107, Imipenem/Cilastatin XNW4107
Activity Status: Active
Last Trial Started: 7/30/2026
Last Trial Ended: 8/30/2025
Trials (12 months): 4
Completed Trials: 8
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.